Eli Lilly, a major pharmaceutical company, has recently partnered with OpenAI to utilize artificial intelligence (AI) in drug discovery efforts. This collaboration aims to invent novel antimicrobials to treat drug-resistant pathogens, addressing a serious global health issue. The use of generative AI in healthcare has enormous potential, with the market size for AI in the healthcare sector projected to reach $187 billion by 2030. The partnership with OpenAI could lead to groundbreaking discoveries and new medicines, potentially diversifying Lilly’s portfolio and improving patient care on a global scale. While the impact of this deal on Lilly’s stock performance remains to be seen, it represents an important step in the company’s future. Lilly already offers leading treatments for various conditions and diseases, and its focus on combating antimicrobial resistance could position it as a key player in the AI healthcare space. Investors are advised to monitor Lilly’s progress in this area and its impact on the business in the upcoming quarters.

Source link

Source link: https://www.fool.com/investing/2024/06/29/eli-lilly-is-teaming-up-with-openai-here-are-3-thi/